Value Assessment Vexes Pharma As China Costs Soar, Prices Fall

Traditionally a low-cost manufacturing haven, China has seen pharma R&D costs increase rapidly although prices for pharmaceuticals have not gone up, forcing officials and executives to explore value assessment and market access approaches in a toughening environment.